ADIAL PHARMACEUTICALS, INC.
ADIAL PHARMACEUTICALS, INC.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Party | - | - | 0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | - | |||||
Accounts Receivable From Securitization | - | - | - | - | - | - | - | - | - | 0 | 1 | |||||
Assets | ||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 5 | 6 | 5 | 6 | 2 | 4 | 5 | 3 | 3 | 0 | 1 | |||||
Assets Current | ||||||||||||||||
Assets Current | 5 | 6 | 5 | 6 | 3 | 4 | 6 | 4 | 3 | 1 | 2 | |||||
Prepaid Expense Current | - | - | - | - | - | - | 0 | 0 | - | - | - | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Indefinite Lived Intangible Assets Excluding Goodw… | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Equity Method Investments | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | |||||
Assets | 5 | 7 | 6 | 7 | 3 | 5 | 7 | 5 | 5 | 3 | 4 | |||||
Liabilities And Stockhold… | ||||||||||||||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | ||||||||||||||||
Liabilities Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Accrued Liabilities And Other Liabilities | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Other Liabilities Current | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Liabilities | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Long Term Debt And Capita… | ||||||||||||||||
Stockholders Equity | ||||||||||||||||
Stockholders Equity | 4 | 5 | 5 | 6 | 2 | 4 | 6 | 4 | 4 | 2 | 3 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 96 | 95 | 92 | 92 | 86 | 86 | 86 | 82 | 73 | 69 | 69 | |||||
Retained Earnings Accumulated Deficit | -92 | -90 | -88 | -86 | -84 | -82 | -80 | -78 | -69 | -67 | -65 | |||||
Liabilities And Stockholders Equity | 5 | 7 | 6 | 7 | 3 | 5 | 7 | 5 | 5 | 3 | 4 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 100 | 100 | 100 | 8,500 | 8,500 | 8,500 | 8,500 | 8,500 | 8,500 | 8,500 | 8,500 | |||||
Common Stock Shares Issued | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Shares Outstanding | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 67.83% | 79.02% | 94.41% | - | - | - | - | - | - | - | - | - |
| 2025 | -12.31% | -49.23% | -29.23% | -12.50% | 0.00% | -12.50% | -3.12% | -25.00% | -34.38% | -16.75% | -19.80% | 5.58% |
| 2024 | - | - | - | 3.09% | 0.00% | 4.12% | 21.21% | 10.10% | -16.16% | -10.67% | -8.00% | -8.00% |
| 2023 | -6.67% | -30.00% | -10.00% | -12.54% | -17.31% | -35.52% | -6.02% | -18.98% | -48.15% | 30.89% | 1.63% | -8.94% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
ADIAL PHARMACEUTICALS, INC. (ADIL) — SEC Financial Statements & Analysis
ADIAL PHARMACEUTICALS, INC. (ADIL) is a pharmaceutical preparations company, incorporated in DE. ADIAL PHARMACEUTICALS, INC. trades on Nasdaq as: ADIL. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ADIAL PHARMACEUTICALS, INC. reported a Debt-to-Equity ratio of 0.41x, a Price-to-Book (P/B) ratio of 0.66 (TTM), at a market cap of $2.45M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.41x
- P/B TTM
- 0.66
- Market Cap
- $2.45M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ADIAL PHARMACEUTICALS, INC. in?
ADIAL PHARMACEUTICALS, INC. (ADIL) operates in the Pharmaceutical Preparations industry.
What is ADIL's market cap?
ADIAL PHARMACEUTICALS, INC. (ADIL) has a market capitalization of $2.45M as of 2026-03-31.
What exchange does ADIL trade on?
ADIAL PHARMACEUTICALS, INC. (ADIL) trades on the Nasdaq.
Where is ADIAL PHARMACEUTICALS, INC. incorporated?
ADIAL PHARMACEUTICALS, INC. is incorporated in DE.